ACE-083
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Musculoskeletal Diseases
Conditions
Musculoskeletal Diseases
Trial Timeline
Sep 1, 2014 → Apr 1, 2016
NCT ID
NCT02257489About ACE-083
ACE-083 is a phase 1 stage product being developed by Merck for Musculoskeletal Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT02257489. Target conditions include Musculoskeletal Diseases.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03943290 | Phase 2 | Terminated |
| NCT02257489 | Phase 1 | Completed |
Competing Products
4 competing products in Musculoskeletal Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochloride | Eisai | Phase 3 | 77 |
| No intervention | Johnson & Johnson | Pre-clinical | 23 |
| Lumiracoxib | Novartis | Approved | 85 |
| Nerve Growth Factor | Lundbeck | Pre-clinical | 20 |